Network Pharmacology and Experimental Verification: SanQi-DanShen Treats Coronary Heart Disease by Inhibiting the PI3K/AKT Signaling Pathway
Through the integrated approach of network pharmacology and molecular docking, we have established that SQDS exerts a multi-component, multi-target, and multi-pathway synergistic therapeutic effect on coronary heart disease. Its mechanism may involve the inhibition of the PI3K/AKT signaling pathway and the reduction of inflammatory factor expression.
Authors
- Liuxiang Feng
- Min Zhao
- Wenhua Li
Institutions
- Xizang Minzu University (CN)
- Qujiang People's Hospital (CN)
Publication Details
- Journal
- Drug Design Development and Therapy
- Published
- 2024-10-01
- DOI
- https://doi.org/10.2147/dddt.s480248
- Citations
- 8
- Primary Topic
- Pharmacological Effects of Natural Compounds
- Type
- article
- Field-Weighted Citation Impact
- 3.73